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Background: Handling of common marmoset (Callithrix jacchus) usually requires chemical restraint. Ketamine has
been associated with muscle damage in primates, while common marmosets, compared to other primates,
additionally display an exceptional high sensitivity to ketamine-associated side-effects. Notably, muscle twitching
movements of limbs and hands, and a marked increase in salivation are observed. We investigated two alternative
intramuscular (i.m.) immobilisation protocols against ketamine (50 mg/kg; protocol 1) in a double-blind randomised
crossover study in ten healthy adult common marmosets for use as a safe reliable, short-term immobilisation and
sedation. These protocols comprised: alphaxalone (12 mg/kg; protocol 2) and 25 mg/kg ketamine combined with
0.50 mg/kg medetomidine (reversal with 2.5 mg/kg atipamezole; protocol 3A). Following completion and
unblinding, the project was extended with an additional protocol (3B), comprising 25 mg/kg ketamine combined
with 0.05 mg/kg medetomidine (reversal with 0.25 mg/kg atipamezole, twice with 35 min interval).
Results: All protocols in this study provided rapid onset (induction times <5 min) of immobilisation and sedation.
Duration of immobilisation was 31.23 ± 22.39 min, 53.72 ± 13.08 min, 19.73 ± 5.74 min, and 22.78 ± 22.37 min for
protocol 1, 2, 3A, and 3B, respectively. Recovery times were 135.84 ± 39.19 min, 55.79 ± 11.02 min, 405.46 ±
29.81 min, and 291.91 ± 80.34 min, respectively. Regarding the quality, and reliability (judged by pedal withdrawal
reflex, palpebral reflex and muscle tension) of all protocols, protocol 2 was the most optimal. Monitored vital
parameters were within clinically acceptable limits during all protocols and there were no fatalities. Indication of
muscle damage as assessed by AST, LDH and CK values was most prominent elevated in protocol 1, 3A, and 3B.
Conclusions: We conclude that intramuscular administration of 12 mg/kg alphaxalone to common marmosets is
preferred over other protocols studied. Protocol 2 resulted in at least comparable immobilisation quality with
acceptable and less frequent side effects and superior recovery quality. In all protocols, supportive therapy, such as
external heat support, remains mandatory. Notably, an unacceptable long recovery period in both ketamine/
medetomidine protocols (subsequently reversed with atipamezole) was observed, showing that α-2 adrenoreceptor
agonists in the used dose and dosing regime is not the first choice for sedation in common marmosets in a
standard research setting.
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The common marmoset (Callithrix jacchus) is fre-
quently used in biomedical research [1,2]. Although cer-
tain procedures can sometimes be performed without
sedation, more complex procedures require immobilisa-
tion. However, limited information is available in the lit-
erature on marmoset chemical restraints [3]. The use of
inhalation techniques is impractical when dealing with
large numbers of animals simultaneously in environ-
ments without an operating theatre. Therefore, keta-
mine is commonly used for immobilisation, either
alone or combined with other sedatives and/or analge-
sics [3-5]. The main disadvantages of ketamine are poor
muscle relaxation, grasping movements of limbs and
hands, and a marked increase in salivation [4,6]. In
addition, ketamine has been associated with muscle
damage in primates [7-9].
Alternatively, sedation with alphaxalone-alphadolone
(SaffanW, AlthesinW) was recommended for marmosets
[3,5,10]. Despite the relatively large injection volume,
no muscle damage was observed [5]. Alphaxalone-
alphadolone was solubilised with CremophorW-EL,
which resulted in adverse effects in dogs, cats, and
humans [11,12] and consequently it was withdrawn from
the market. Recently, a new formulation of alphaxalone
without alphadalone and solubilised with the aid of cy-
clodextrin rather than CremophorW-EL became available
(AlfaxanW). This is a short-acting, injectable anaesthetic
agent for the induction and maintenance of general an-
aesthesia in dogs and cats [13-15]. Its clinical off-label
administration has been described in several species, in-
cluding ponies, pigs, and goats [16-22].
A short-term anaesthesia regimen frequently used in
dogs and cats is ketamine combined with medetomidine
[23,24]. Concurrent use of medetomidine reduces the
amount of ketamine required, induces additional anal-
gesia as well as curtailing increased muscle tone and
salivation. An important advantage is the quick recovery
to normal function following reversal of medetomidine
with the specific antagonist atipamezole in dogs and
cats [23-26]. In addition, the combination ketamine/
medetomidine caused markedly less damage to muscle
tissue at injection sites than did the single use of keta-
mine in rats [27]. The use of ketamine/medetomidine
has been described in several primate species [27-35],
but these reports offer little guidance related to its prac-
tical implementation in the common marmoset.
Due to the lack of knowledge on safe, reliable and short-
term sedation protocols in the common marmoset, we
designed a crossover study to assess and compare the ef-
fects of ketamine, ketamine-medetomidine (reversed with
atipamezole) and alphaxalone administered i.m. for
allowing the undertaking of minor invasive procedures
such as blood collection from the femoral vein, tuberculintesting, routine veterinary interventions such as minor
surgical procedures or wound care, radiography, and
ultrasonography.
Methods
Animals, housing, and care
Ten (5 male and 5 female) healthy adult common mar-
mosets (Callithrix jacchus), age 3.2 ± 1.4 years and mean
bodyweight of 364 ± 27 g all originated from the Bio-
medical Primate Research Centre (BPRC, Rijswijk, The
Netherlands). All monkeys received a complete physical,
haematological, and biochemical examination before the
study started. Only animals with all values within the
normal range were included. They remained under in-
tensive veterinary supervision during the entire study
period. Animals were housed with a same-sex buddy in
spacious cages (150 × 75 × 185 cm) enriched with
branches and toys, in compliance with the new EU dir-
ective 63/2010. The animals were fed commercial mon-
key pellets (SsniffW, Soest, Germany) supplemented with
Arabic gum and limited amounts of fresh fruit. Drinking
water was available ad libitum. Room temperature was
23.2-26.8°C, with a 12 hour light:dark cycle. Food was
removed 16 hours prior to sedation but water intake was
never restricted.
Ethical consideration
The experimental protocol (DEC-BPRC number: # 665)
was approved by the Animal Experiments Committee
(DEC) of the BPRC. The DEC based its decision on ‘De
Wet op de Dierproeven’ (The Dutch ‘Experiments on
Animals Act’, 1996) and on the ‘Dierproevenbesluit’
(The Dutch ‘Experiments on Animals Decision’, 1996).
Both documents are available online at http://wetten.
overheid.nl.
Experimental design and drug administration
The study was initially performed in three sessions, with
a 28-day washout interval in a prospective, double
blinded crossover design. Each animal was randomised
to receive one of the following sedation protocols: (1)
Ketamine hydrochloride (Ketamine 10%; Alfasan Nederland
BV, Woerden, NL, 100 mg/ml), at a dose of 50 mg/kg
ketamine i.m.; (2) alphaxalone (Alfaxan; Vetoquinol B.
V., ‘s-Hertogenbosch, NL, 10 mg/ml), at a dose of
12 mg/kg alphaxalone i.m.; (3A) 25 mg/kg ketamine,
and medetomidine hydrochloride (Sedastart; AST Farma
B.V., Oudewater, NL, 1 mg/ml), at a dose of 0.5 mg/kg
i.m. combined in the same syringe just before its use, re-
versed with atipamezole hydrochloride (Sedastop; AST
Farma B.V., Oudewater, NL, 5 mg/ml), at a dose of
2.5 mg/kg atipamezole i.m. after 10 min of immobilisation.
To maintain a double-blind design and to exclude any ef-
fect of mechanical damage from the amount of fluid i.m.
Table 1 Scorecard for quality of induction, immobilisation and recovery
Score Quality Character
1 Good No vocalisation, salivation, compulsive licking or sneezing. No increased attention towards injection site, no involuntary/
uncoordinated muscle activity
2 Satisfactory Some vocalisation and/or involuntary/uncoordinated muscle activity, salivation, compulsive licking, sneezing, some
discomfort from injection (< 5 min)
3 Unsatisfactory Violent struggling/no immobilisation effectuated, severe discomfort from injection (increased attention towards injection
site > 5 min), excessive salivation, vomiting, compulsive licking, sneezing, involuntary muscle activity
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B.V., Oss, NL) was added to ascertain that all volumes
injected were identical. Animals that did not receive
atipamezole received an equal volume of saline, 10 min
after immobilisation was recorded.
Twenty eight days after the third sedative session
(day 112), following unblinding of the dataset, it was
decided to add an additional sedation round (protocol
3B) with ketamine (25 mg/kg) combined with a tenfold
lower medetomidine dose (0.05 mg/kg) followed by
atipamezole injection of 0.25 mg/kg after 10 min and
similar amount 35 min later if the recovery phase had
not ended.
While it is standard to use sedation when handling
common marmosets, for the purpose of this study we
avoided this procedure for bodyweight measurement
and blood sampling because unsedated control values to
determine the effect of the sedation were required.
Prior to each sedation, and one and two days following
sedation, bodyweight was registered to determine the
correct dosage of the sedative, and to determine the pos-
sible effect of sedation on bodyweight development.
Marmosets were trained to voluntarily enter a Perspex
cylinder and were taken out of their cage by means of
this cylinder. The cylinder with the animal in it was
placed on a weighing scale as a non-invasive means of
assessing the bodyweight.
For injection, one person manually restrained the ani-
mal while a second person administered the anaesthetic
volume i.m. into the quadriceps muscle mass on the an-
terior thigh, into the left or right quadriceps femoris,
using a 26G needle. Care was taken that the drugs were
not injected directly into the circulation.
After injection of the sedative, each marmoset was re-
leased into its home cage, where it was monitored until
immobilisation was achieved. Once immobilised, the an-
imals were taken to an adjacent quiet, temperature-Table 2 Scorecard for muscular tension
Score Quality Character
0 No muscle tension Complete relaxati
1 Normal muscle tension Partial relaxation
2 Increased muscle tension Rigidity in muscle
The muscular tension was assessed by resistance to flexion of limbs (leg muscle ten
opening the jaws (jaw tension was evaluated by pulling the lower jaw open by ancontrolled room (24°C) for measurements. Procedures
were carried out using routine practice standards for
short minimally invasive procedures, without supportive
care (i.e. external heat or secured airway). The marmo-
sets were breathing room-air spontaneously throughout
the experiment. When the immobilisation period ended,
the animals recovered in their home cage on an open
non-heated blanket, facilitating visual control by the ob-
server during the recovery period.
Determination of induction, immobilisation and recovery
characteristics
For each sedation event, induction, immobilisation, and
recovery times were recorded. Induction time was de-
fined as the time between injection and loss of postural
tonicity. Immobilisation time was defined as the time
from the loss of postural tonicity to the animal’s first at-
tempt to lift its head. Recovery time was defined as the
time from the animal’s first attempt to lift its head until
the moment that the marmoset could walk and climb
confidently in the restricted confines of its cage and
could be reunited safely with its companion. Total pro-
cedure time was defined as the sum of induction time,
immobilisation time, and recovery time.
For each sedation event, the quality of induction and
recovery as a whole and at 3-min intervals during immo-
bilisation were scored on an ordinal scale by a
treatment-blinded observer (Table 1). The reliability of
immobilisation was judged by the degree of muscular
tension (Table 2) and pedal withdrawal reflex (Table 3),
while sedation was judged by the palpebral reflex
(Table 4) [36]. To allow for a meaningful comparison be-
tween groups, immobilisation quality- and reflex-scores
were censured from statistical analysis after 9 minutes.
Only descriptive statistics were performed on the immo-
bilisation quality data and reflex scores from 9 minutes
into the immobilisation onwards.on, adequate muscle relaxation for performing minor invasive procedures
s
sion was evaluated by flexion and extension of the left rear leg) and by
index finger).
Table 3 Scorecard for the pedal withdrawal reflex
Score Quality Character
0 No reflex There was no increased muscle tension and/or bending of the knee for at least one second after removing the haemostat
1 Normal reflex There was muscle tension and/or bending of the knee
2 Increased reflex There was increased muscle tension, bending of the knee, and muscle vibrations/involuntary movements of other limbs
The pedal withdrawal reflex was determined by applying a haemostat (Hartman baby mosquito BH104R, straight, 100 mm, 4″) on the first clip for 1 second on
phalanx III, just above the nail of the left rear leg.
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systolic, diastolic, and mean arterial blood pressure
(SAP, DAP, and MAP, respectively) were recorded at
3-min intervals using a non-invasive oscillometric de-
vice (vetHDO monitor with MDSoftware, using a
CriticonWSoft-cufW, size: I, colour: white) at the base of
the tail. Respiratory rate (RR) was determined by ob-
serving thoracic excursions over a 30 second period
and multiplied by two. Pulse haemoglobin oxygen sat-
uration (SpO2) was measured using an earlobe clip of a
veterinary pulse oximeter (Ohmeda biox 3740; BOC
Health Care, Inc., Louisville, USA) applied to the right
hand. Rectal body temperature was monitored at 3-min
intervals using a digital thermometer (MicrolifeWVet-
temp; MicrolifeW, Widnau, Switzerland) with a meas-
urement range of 32°C to 42.9°C. To allow for a mean-
ingful comparison between groups, PR, MAP, RR,
SpO2, and rectal body temperature were censured from
statistical analysis after 9 minutes.
Blood sampling
To determine possible local myotoxic effects of the
injected formulations, levels of AST, LDH, and CK were
determined in serum. Samples (200 μl blood) were taken
from unsedated animals prior to administration of the
sedative and 24 and 48 h post dosing. Control samples
from unsedated animals were collected on day 0, 1, 2,
140, 141, and 142. Samples were collected by one person
restraining the animal while a second person performed
the blood sampling by inserting a needle (26 gauge) per-
cutaneously into the vena saphena, confirmed by self-
filling of the needle tip with blood, of which blood
was collected for testing. Afterwards, firm pressure was
applied to the sample site for 2 min to minimise haem-
orrhage rises. The samples were processed immediately
with a Cobas IntegraW 400 plus (F. Hoffmann-La Roche





The palpebral reflex was tested by lightly touching the medial canthus of the left eStatistical analysis
All statistical analyses were performed with the R lan-
guage and environment for statistical computing (R
Foundation for Statistical Computing, Vienna, Austria.
ISBN 3-900051-07-0, URL http://www.R-project.org). To
determine statistical significance in induction, immobil-
isation, and recovery times, paired t-tests were
performed for the six pair-wise comparisons (P1 versus
P2, P1 versus P3A, P1 versus P3B, P2 versus P3B, P2
versus P3B and P3A versus P3B). The quality of the sed-
ation phases was analysed using the non-parametric
Wilcoxon’s signed rank test. To adjust for multiple tests
a Bonferroni correction was applied: the p value for stat-
istical significance was set at 0.05/6 = 0.00833. Clinical
chemistry values (AST, LDH and CK) and body weight
were analysed with mixed linear models and ensuing pa-
rameters estimates are presented with 95% confidence
intervals, p values of <0.05 were considered statistically
significant.
Results
Duration and quality of the sedative protocols
Induction, immobilisation, recovery and total procedure
time are shown in Figure 1 and Table 5. Induction time
of protocol 2 was significantly longer than that for
protocol 1 (p = 0.0016, paired t-test), protocol 3A (p <
0.0005, paired t-test), and protocol 3B (p = 0.0001, paired
t-test). There was no significant difference in the other
comparisons. Immobilisation time in protocol 2 was of a
longer duration than protocol 1, but failed to achieve
statistical significance (p = 0.011). Immobilisation times
in protocol 2 were significantly longer than those ob-
served for protocols 3A and 3B (p = 0.0001 and 0.0012,
respectively), both with administration of atipamezole
after 10 min of immobilisation. Recovery times for
protocol 1 were significantly shorter than protocol 3A
and 3B (p values < 0.0001, paired t-test). Protocol 2Character
No narrowing of the eyelids or muscle movement
Delayed and/or incomplete closing of the eyelids
The eyelids immediately close fully
ye with a dry cotton swab without touching the cornea.
Figure 1 Induction, immobilisation, recovery and total procedure time in minutes, in each sedative protocol per individual. P1 = protocol 1,
P2 = protocol 2, P3A = protocol 3A, and P3B = protocol 3B. Each symbol represents an individual animal throughout all panels. Top of the box
indicates upper quartile, middle is median and bottom is lower quartile.
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then the other protocols (p < 0.0001, paired t-test, for all
comparisons). There was a significant difference in the
recovery times between protocols 3A and 3B (p = 0.0005,
paired t-test). In protocol 3A and 3B, a relatively long (at
least 1 hour) period of apathy was observed in all mon-
keys after they had initially sat upright. During this time,
the marmosets clung to the wire of their cage, or to
branches, and remained there for prolonged periods,
during which they did not react to any external stimuli.
Quality assessments
Quality of induction and recovery as a whole and of im-
mobilisation at 3, 6, and 9 min are shown in Figure 2.
Quality of induction never reached the unsatisfactory
score of 3 in any sedation protocols used. In protocol 1,
8 monkeys were given a score of 2 (2 due to vocalisation
and salivation, 2 due to vocalization alone, and 4 due to
salivation alone). In protocol 2, 4 marmosets scored a 2
(vocalisation during injection). During protocol 3A, 3
animals scored a 2 (vocalisation only); whereas inTable 5 Induction, immobilisation, recovery, and total proced
Protocol 1 Proto
Induction time 1.24 ± 0.55 2.54 ±
Immobilisation time 31.23 ± 22.39 53.72
Recovery time 135.84 ± 39.19 55.79
Total procedure time 168.32 ± 45.60 112.0protocol 3B, a total of 6 animals scored a 2 (4 due to
salivation, 1 monkeys due to salivation and vocalisation
and 1 animal due to vocalisation during injection).
The quality of immobilisation was measured every
3 min for all animals during immobilisation. Because in
protocol 1 some animals already started to recover after
9 min, detailed comparison of all groups was only pos-
sible for the first 9 min (Figure 2). The quality of immo-
bilisation after 9 min is described below. In protocol 1,
two animals scored a 3 while immobilised with keta-
mine, due to periods of apnoea, combined with involun-
tary limb movement. Five monkeys scored a 2 due to an
observation of salivation or involuntary muscle move-
ment. In one of those animals, quiet vocalisation and
muscle twitching was observed. Three animals were
given a score of 1. In protocol 2, no salivation was ob-
served, but all marmosets displayed muscle twitches
near the end of immobilisation (score 2). In protocol 3A,
no marmoset was given a score of 3, while only two ani-
mals scored a 2 due to salivation or involuntary muscle
movement. In protocol 3B, however, one marmoseture time in min (mean ± SD) in each sedative protocol
col 2 Protocol 3A Protocol 3B
0.65 1.17 ± 0.42 1.20 ± 0.31
± 13.08 19.73 ± 5.74 22.78 ± 22.37
± 11.02 405.46 ± 29.81 291.91 ± 80.34
5 ± 15.30 426.37 ± 29.11 315.89 ± 88.95
0































9 min6 min3 min
Figure 2 Quality of induction, immobilisation, and recovery, scored in each sedative protocol. A = induction, B = immobilisation,
C = recovery. p1 = protocol 1, p2 = protocol 2, p3A = protocol 3A, and p3B = protocol 3B.
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protocol 1). A total of four marmosets reached a score
of 2 due to salivation or involuntary muscle movement.
Eight and five animals for group 3A and 3B respectively
were given a score of 1.
Quality of recovery was given a score of 1 for one ani-
mal for group 1, all animals for group 2 and two and
four animals for group 3A and 3B respectively. Nine ani-
mals sedated with ketamine scored a 2 due to salivation.
With protocol 3A, six marmosets scored a 2, and with
protocol 3B, four animals were given a score of 2, all
because of excessive salivation. In both protocols 3A
and 3B, two marmosets scored a 3 due to excessive sali-
vating and vomiting. The quality of recovery was sig-
nificantly lower in protocol 1 as compared to protocol
2 (p = 0.006, Wilcoxon signed rank test).Physiological parameters
During immobilisation, cardiorespiratory parameters
were continuously scored with 3-min interval. The 3, 6,
and 9 min data are shown in Table 6. No significant dif-
ferences were observed for these parameters between
the used protocols. RR, SpO2, PR, and MAP values
scored during the total immobilisation period were gen-
erally within clinically acceptable limits during all proto-
cols and there were no fatalities. However, in protocol 1,
two animals experienced a short period of apnoea. In
protocol 3B, one marmoset (same animal showed this
also with protocol 1) experienced again an apnoea
period. No cyanosis of the visible mucous membranes
was observed.
In all sedation protocols, monkeys were between 38–
39.5°C at the beginning of each procedure; the rectal
Table 6 Cardiorespiratory parameters averages and
standard deviation values
3 min 6 min 9 min
P1 PR 367 ± 36* 371 ± 23 348 ± 50*
P2 PR 330 ± 52 320 ± 51 310 ± 51
P3A PR 236 ± 35 230 ± 32 221 ± 19
P3B PR 263 ± 29* 257 ± 18 237 ± 15
P1 MAP 87 ± 8 91 ± 17 85 ± 16*
P2 MAP 94 ± 21 94 ± 24 96 ± 28
P3A MAP 75 ± 11 64 ± ±6 63 ± 8
P3B MAP 96 ± 24 87 ± 21 89 ± 25
P1 Body Temp 38.8 ± 0.5 38.4 ± 0.5 37.8 ± 0.4*
P2 Body Temp 38.9 ± 0.5 38,6 ± 0.4 38.3 ± 0.5
P3A Body Temp 38.8 ± 0.2 38,2 ± 0.3 37.8 ± 0.3
P3B Body Temp 39.2 ± 0.4 38.9 ± 0.4 38.5 ± 0.4
P1 SpO2, 86 ± 6 86 ± 5 86 ± 15*
P2 SpO2, 80 ± 9 83 ± 10 80 ± 11
P3A SpO2, 93 ± 3 92 ± 3 93 ± 3
P3B SpO2, 86 ± 7 84 ± 7 84 ± 8
P1 RR 58 ± 17 56 ± 10 58 ± 14*
P2 RR 41 ± 10 38 ± 9 38 ± 6
P3A RR 61 ± 18 56 ± 14 57 ± 10
P3B RR 58 ± 12 59 ± 13 59 ± 14
PR (beats/min), MAP (mm Hg), body temperature (°C), SpO2 (per cent), and RR
(per min) in the tested sedation protocols during the first 9 min of the
immobilisation period, with 3 min interval. P1 protocol 1, P2 protocol 2, P3A
protocol 3A, and P3B protocol 3B. n = 10 unless specified, *n = 9.
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20 min. Temperature measurements taken during recov-
ery tended to show a progressive decrease, even below
32°C, until normal activity was resumed.
No effects of the atipamezole injection(s) on physio-
logical parameters were observed.
Reliability
For all monkeys muscle tension, palpebral reflex
and withdrawal reflex were continuously scored with
3-min interval. The 3, 6, and 9 min data are shown
in Figure 3A, B, and C.
The data of the whole immobilisation period was after-
wards judged and is represented in Table 7. For the
muscle tension, data protocol 1: five out of the eight that
did not reach a score of 0 never reached a score of 1 ei-
ther. Data protocol 2: all animals’ muscle tension scores
were initially 0 and increased to a score of 1 towards the
end of the immobilisation period. Data protocol 3A/B:
Other protocols differed in scores between 0 and 1, with
only a few marmosets reaching a score of 2.
The palpebral reflex scores differed markedly in time
and between individuals, with some animals neverachieving a score of 0. All animals under all sedative
protocols used achieved a score of 2 before the end of
immobilisation. Three animals in protocol 2 did not
reach a score of 0, but were all given a score of 1 at sev-
eral points during the observations. Only one of the four
animals in protocol 3A that did not reach a score of 0
was never given a score of 1. Two of the seven animals
in protocol 3B did not reach a score of 0 were never
given a score of 1.
Regarding the withdrawal reflex, no score of 2 was
given to any animal during any of the sedations. Several
animals never reached a score of 0, with the exception
of protocol 2, as all these animals reached a score of 0.
Assessment of muscle damage
The first day after sedation, AST levels (Figure 4A) had
increased significantly for protocols 1, 3A and 3B as well
as for the control protocol (all p < 0.05; Table 8). A small
but statistically non-significant increase in AST levels
was observed for protocol 2 (Table 8). AST levels
remained elevated on the second day after sedation for
protocols 1 and 3 as well as for the control protocol (all
p < 0.05; Table 8). A statistically non-significant increase
in AST levels was observed for protocols 2 and 3B
(Table 8).
The first day after sedation, LDH levels (Figure 4B)
had increased significantly for protocols 1 and 3A (all p
< 0.05; Table 8). A small but statistically non-significant
increase in LDH levels was observed for protocols 2 and
3B (Table 8). The increase in LDH levels continued for
animals in the control group and protocol 3A; day 2
LDH levels were significantly elevated as compared to
day 0 (Table 8). LDH levels remained elevated in proto-
cols 1, 2 and 3B but this failed to reach statistical signifi-
cance (Table 8).
CK levels increased significantly one day after sedation
in all protocols as well as in the control protocol
(Table 8) (Figure 4C). The increase in CK levels was sig-
nificantly higher in protocols 1 and 3 as compared to
controls or protocol 2 (Table 8). CK levels decreased
slightly as compared to day 1, but remained elevated on
the second day after sedation in all groups (Table 8).
Body weight
The first day after sedation body weight had significantly
dropped for protocol 3A, whilst non-significant changes
were observed for the control protocol and protocols 1,
2 and 3B (Table 8; Figure 5). The second day after sed-
ation body weights did not differ significantly from base-
line values for any of the protocols under investigation.
Discussion
This is the first study that directly compared the effect
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Figure 3 Reliability in the tested sedation protocols during the first 9 min of the immobilisation period, with 3 min interval (A)
Muscular tension (B) palpebral reflex (C) pedal withdrawal reflex. p1 = protocol 1, p2 = protocol 2, p3A = protocol 3A, and p3B = protocol 3B.
n = 10 unless specified; *n = 9.
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term sedation protocol, with at least 10 min of immobil-
isation. In this study, alphaxalone was shown to be su-
perior for sedation in marmosets. Due to the relatively
long recovery period, ketamine-medetomidine is not the
first choice in the used dose and dosing regime for sed-
ation in marmosets.
All induction times were less than 5 min. Induction
time, defined as the time between injection and loss
of postural tonicity, was a very accurate measure
since the transition from “awake” to “immobilised” was
very distinct.The duration of immobilisation indicated that the
alphaxalone dosage could be used safely for procedures
lasting approximately 40 min. Additionally, all marmo-
sets displayed muscle twitches near the end of immobil-
isation. Alphaxalone is described in cats and dogs to
cause myoclonic twitches [14]. In marmosets we ob-
served these muscle twitches only just before awakening,
which could be interpreted as 'warning of awakening’
signs towards the end of the immobilisation period. The
shorter duration of immobilisation of the other protocols
demonstrate that those protocols can only be used safely
for procedures lasting less than 15 min. Notably, in
Table 7 The reliability in total of the tested sedation
protocols during the immobilisation
Palpebral reflex Withdrawal reflex Muscle tension
P1 P2 P3A P3B P1 P2 P3A P3B P1 P2 P3A P3B
Good 2 7 6 3 7 10 8 8 6 10 9 9
Not Good 8 3 4 7 3 0 2 2 4 0 1 1
P1 protocol 1, P2 protocol 2, P3A protocol 3A, and P3B protocol 3B. The
reliability was judged by the degree of muscular tension, pedal withdrawal
reflex, and palpebral reflex and was afterwards divided into ‘good’ and ‘not
good’. The number of animals, which reached at least the palpebral score of 0
were defined as ‘good’ and the animals that never reached a score lower than
1 as ‘not good’. The number of animals reaching a withdrawal score of 0 was
judged as ‘good’ and animals never reaching a score lower than 1 were
judged as ‘not good’. The number of animals that reached a muscle tension
score of maximum 1 was judged as ‘good’ and animals that reached a score of
2 were judged as ‘not good’.
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10 minutes of immobilisation, thus in this study we can
not report on the duration of immobilisation in these 2
protocols when atipamezole was administered later or
not at all.
In our initial set-up, we found an undesirable long re-
covery time in protocol 3A, despite the administration
of atipamezole. This was surprising, as it was expected
to be shorter than for all other sedatives due to the ad-
ministration of a specific antagonist of medetomidine:
atipamezole. Short total procedure times are preferred
as it minimises the time between the animal’s removal
from and return to its social group, and gives the advan-
tage of the animal being able to consume food rapidly post
sedation. In cats and dogs, reversal with atipamezole re-
sults in a quick and full recovery (3–5 min) [23,24]. This
combination is also described as a common induction re-
gime for non-human primates [3]. Our observations show
the opposite in marmosets, and are in line with a study by
Young [35], who found no difference in recovery times be-
tween macaques that received ketamine-medetomidine re-
versed with atipamezole compared to ketamine only.
Although ketamine supplemented with a lower dose of
medetomidine and an additional atipamezole injection
tended to result in a shorter recovery time compared to
the high medetomidine dose group, the recovery duration
remained protracted and unacceptable. At the moment,
we have no explanation for this finding. Particularly in
protocol 3A and 3B, after an initial arousal involving sit-
ting upright and an attempt to climb, the animals spent
several hours in complete apathy. During this period of
apathy it was not safe to reunite them with their compan-
ion, as marmosets engaged in a conflict of dominance
when one was temporarily not fully awake. This demon-
strates that recovery should be well defined and is not
merely waking-up after sedation.
The drug dosages were chosen according to institute-
wide practices and published references [37,38]. Ourexperience with the used protocols show that they were
sufficient for minor invasive procedures, such as blood
collection from the femoral vein, tuberculin testing,
wound care, and radiography (data not shown). The ob-
served duration times showed that the doses and/or use
of antagonists were well chosen, as induction time for all
protocols was very short, and immobilisation times,
without taking protocol 2 into account, were not long
enough to allow a dose reduction without increasing the
risk of creating a immobilisation period shorter than
10 min; our dosage can only be used for minimal proce-
dures requiring less than 15 min, and maybe even then a
loss of reliability can occur.
Considering the overall quality of the different proto-
cols tested, sedation using alphaxalone shows to be the
most optimal as we observed no (excessive) salivation,
apnoea, involuntary muscle movement, or vomiting for
this protocol. The side effects we have observed with
ketamine in protocol 1 are consistent with literature
[4-6]. Retching and vomiting during recovery, as seen in
protocol 3A and 3B, is known to be a common side effect
of α2-adrenergic agonists [39]. However, retching and
vomiting were not seen in macaques given ketamine-
medetomidine [35]. The observed retching and vomiting
during recovery, could also be due atipamezole, however,
no information is available about the side effects of
atipamezole in primates [28-30,32-35].
The most marked effect on physiological parameters
was hypothermia, which probably delayed recovery
from sedation in all animals in all sedation protocols,
but all recoveries were uneventful and no long-term
side effects were observed. Nevertheless, the use of a
heating pad or a lamp would be beneficial and should
always be used during sedation and recovery, as de-
scribed for macaques [40].
The limited changes in PR, MAP, RR and %SpO2 in all
protocols remained within a clinically acceptable range
in most animals, with the exception of two animals in
which apnoea was scored during protocol 1 and one also
during protocol 3B between the atipamezole injections,
which suggests that the apnoeae were a ketamine side-
effect. Nevertheless, the recovery times of both animals
were not prolonged compared to the other animals in
the same protocol and the animals recovered without
intervention. In conscious unrestrained marmosets an
PR of 230 ± 26 bpm is described [41]. The small drop in
PR and MAP observed at the start of the sedation pro-
cedure (Table 6) was possibly due to a deepening of the
plane of sedation, as the drugs were absorbed from the
injection site - and rose in the end. In dogs and cats,
bradycardia is consistently seen with the use of
medetomidine due to a combination of central reduction
in the sympathetic drive to the heart and reflex brady-
cardia following peripheral vasoconstriction [23,24,42],
AB
C
Figure 4 Blood values of each sedative protocol (A) AST, (B) CK and (C) LDH. Data presented per individual at day 0, 1, and 2. Separate
panes represent the sedation protocols (PC = control protocol, P1 = Protocol 1, P2 = Protocol 2, P3A = Protocol 3A, P3B = Protocol 3B). Each
symbol represents an individual animal throughout all panels.
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Table 8 Estimated changes in muscle damage indicators
(AST, LDH, and CK) and body weight one and two days
after procedures
Day 1
AST Est (95% CI) PC P1 P2 P3A P3B
PC 198.8 (8.5 to 389.1) ** NS *** NS
P1 526.0 (335.7 to 716.3) ** *** *** *
P2 79.4 (−110.9 to 269.7) NS *** *** NS
P3A 1123.2 (932.9 to 1313.5) *** *** *** ***
P3B 246.4 (56.1 to 436.7) NS * NS ***
LDH Est (95% CI) PC P1 P2 P3A P3B
PC 78.5 (−119.6 to 276.6) NS NS *** NS
P1 299.2 (101.1 to 497.3) NS NS *** NS
P2 40.0 (−158.1 to 238.1) NS NS *** NS
P3A 795.4 (597.3 to 993.5) *** *** *** ***
P3B 43.3 (−154.8 to 241.4) NS NS NS ***
CK Est (95% CI) PC P1 P2 P3A P3B
PC 7.2 (4.0 to 12.9) *** NS *** NS
P1 37.8 (21.1 to 67.7) *** *** NS **
P2 3.9 (2.2 to 7.0) NS *** *** *
P3A 74.2 (41.5 to 132.8) *** NS *** ***
P3B 11.0 (6.2 to 19.7) NS ** * ***
Body Weight Est (95% CI) PC P1 P2 P3A P3B
PC −0.9 (−4.5 to 2.7) NS NS ** NS
P1 0.5 (−3.1 to 4.1) NS NS *** *
P2 1.8 (−1.8 to 5.4) NS NS *** **
P3A −8.5 (−12.1 to −4.9) ** *** *** NS
P3B −5.1 (−8.7 to −1.5) NS * ** NS
Day 2
AST Est (95% CI) PC P1 P2 P3A P3B
PC 286.0 (34.2 to 537.8) NS NS *** NS
P1 362.9 (111.1 to 614.7) NS NS *** NS
P2 96.8 (−155.0 to 348.6) NS NS *** NS
P3A 1019.7 (767.9 to 1271.5) *** *** *** ***
P3B 239.8 (−11.9 to 491.6) NS NS NS ***
LDH Est (95% CI) PC P1 P2 P3A P3B
PC 217.8 (13.7 to 421.9) NS NS NS NS
P1 137.8 (−66.3 to 341.9) NS NS * NS
P2 33.9 (−170.2 to 238.0) NS NS ** NS
P3A 430.1 (226.0 to 634.2) NS * ** **
P3B 72.2 (−131.9 to 276.3) NS NS NS **
CK Est (95% CI) PC P1 P2 P3A P3B
PC 6.8 (3.3 to 13.8) NS NS * NS
P1 8.6 (4.2 to 17.6) NS * NS NS
P2 2.8 (1.4 to 5.8) NS * *** NS
P3A 21.9 (10.7 to 44.8) * NS *** ***
Table 8 Estimated changes in muscle damage indicators
(AST, LDH, and CK) and body weight one and two days
after procedures (Continued)
P3B 4.2 (2.0 to 8.5) NS NS NS ***
Body Weight Est (95% CI) PC P1 P2 P3A P3B
PC 0.2 (−3.9 to 4.3) NS NS NS NS
P1 1.9 (−2.2 to 6.0) NS NS NS *
P2 2.1 (−2.0 to 6.2) NS NS * *
P3A −2.4 (−6.5 to 1.7) NS NS * NS
P3B −3.5 (−7.6 to 0.6) NS * * NS
PC control values, P1 protocol 1, P2 protocol 2, P3A protocol 3A, and P3B
protocol 3B. Changes in AST, LDH and body weight are presented as day X –
day 0 values; changes in CK are presented as fold increases day X/day 0 values
(95% CI). The columns labelled PC, P1, P2, P3A and P3B summarise between
treatment differences (NS = not significant, * < 0.05, ** < 0.01, *** < 0.001).
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mosets there was no significant difference observed in
blood pressure drop between the ketamine and both
ketamine-medetomidine groups. The decrease in PR is
likely to be central in origin, although an initial transient
hypertension would probably not have been detected.
In the current study, the marmosets sedated with
alphaxalone had a lower, although not significantly, RR
when compared to the other sedation protocols, how-
ever not significant. This lower RR for alphaxalone is
also described in dogs and cats [12,14]. However, the %
SpO2 values did not differ significantly between the pro-
tocols. The recorded %SpO2 levels were lower than the
generally accepted minimum of 95%, which indicates a
certain level of hypoxia. However, the recorded %SpO2
may have been not reliable due to a bias caused by the
peripheral vasoconstriction effect of medetomidine or
due pigment interference with the sensor’s capacity to
read accurately [Feiner et al. 2007 [43]].
The withdrawal reaction and palpebral reflex, together
with muscle tension, were used to determine the levels
of sedation and analgesia in the present study [29,36].
However, some anaesthetics not only sedate animals and
produce analgesia but they also interfere with the re-
sponses used to measure these conditions. Ketamine is
known to induce deep sedation without reducing the
palpebral reflex [36,44]. In contrast, in animals sedated
with alphaxalone, there is a reduced palpebral reflex
suggesting that this anaesthetic does not interfere with
this response. In the present study, alphaxalone induced
the deepest sedation and analgesia as measured by these
responses. No further literature is available regarding the
analgesic effects of alphaxalone in marmosets.
In addition, as described in other studies [32,35], a
combination of medetomide and ketamine provides
more muscle relaxation than ketamine alone.
Increased AST, LDH, and CK levels in protocol 1
were indicative for local myotoxicity of the injected
Figure 5 Body Weight values of each sedative protocol. Data presented per individual at day 0, 1, and 2. Separate panes represent the
sedation protocols (C = control protocol, P1 = Protocol 1, P2 = Protocol 2, P3A = Protocol 3A, P3B = Protocol 3B).
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lished data on local myotoxicity of the injected formula-
tions in marmosets and other primates [7-9]. Protocol 2
is preferred in marmosets, as it did not cause muscle
damage as indicated by the lack of increase in AST,
LDH and CK values, despite the relatively large injection
volume. This is in according to literature about the use
of Saffan in primates [5].
Bodyweight loss was highest in protocol 3A compared
to the other protocols, explainable by the fact the ani-
mals had a much longer recovery time in which they
were not able or willing to eat. The difference between
protocol 3A and 3B shows that sedative dosages need to
be chosen well as small dose changes indirectly influence
important parameters as bodyweight.
Conclusion
The aim of this study was to find a good, short-term
sedation protocol, with at least 10 min of immobilisa-
tion. Our finding that alphaxolone showed the shortest
total procedure time combined with the longest immo-
bilisation time demonstrate that alphaxalone has major
practical advantages over the other sedative protocols
tested.
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